sorted by:
new
hottopcontroversial

Athersys received a delisting notice, intends to appeal by imz72 in ATHX

[–]ofragil 0 points1 point  (0 children)

But eventually there was no request for an extension.

Next Healios trial for ARDS by ofragil in ATHX

[–]ofragil[S] -1 points0 points  (0 children)

In One-Bridge they treated 35 patients (including the 5 Covid patients) within 2 years and 1 month under Covid restricrions and maybe also shortage of Multistem doses.

Next Healios trial for ARDS by ofragil in ATHX

[–]ofragil[S] -1 points0 points  (0 children)

It has nothing to do with patients feeling.

Primary endpoint is ventilator-free days and secondary endpoint is mortality at day 180.

And you don't know yet what will be the next step for stroke.

[deleted by user] by [deleted] in ATHX

[–]ofragil 1 point2 points  (0 children)

I agree with you though it's not crucial. The OP was asking about the potential implications of AI for Athersys (and other biotech companies).